Cyclerion Therapeutics (CYCN) Cash from Financing Activities (2018 - 2025)

Cyclerion Therapeutics' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $1.8 million for Q3 2025.

• In Q3 2025, Cash from Financing Activities changed N/A year-over-year to $1.8 million; the TTM figure through Sep 2025 stood at $3.1 million (changed N/A YoY), while the FY2023 annual figure was $5.0 million, up 17224.14% from the prior year.
• Cash from Financing Activities was $1.8 million for Q3 2025 at Cyclerion Therapeutics, up from -$130000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $30.6 million in Q2 2021 to a low of -$130000.0 in Q2 2025.
• Historically, Cash from Financing Activities has averaged $3.8 million across 3 years, with a median of $43000.0 in 2021.
• The sharpest annual moves came in 2021 and 2022: Cash from Financing Activities surged 2600.0% in 2021, then slumped 99.94% in 2022.
• A 3-year view of Cash from Financing Activities shows it stood at $85000.0 in 2021, then tumbled by 85.88% to $12000.0 in 2022, then soared by 15116.67% to $1.8 million in 2025.
• The last three Cash from Financing Activities figures came in at $1.8 million (Q3 2025), -$130000.0 (Q2 2025), and $1.4 million (Q1 2025), per Business Quant data.